Company Name Hallux
Mailing Address Undisclosed Orange, CA 92856 USA
Company Description Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride, the highly effective leading anti-fungal, directly and selectively to the site of infection.
Proceeds Purposes The new capital will be deployed to advance Hallux’s proprietary terbinafine micro-insert dosage form into phase 2A clinical trials, with the goal of demonstrating safety, efficacy, and tolerability in patients with distal lateral subungual onychomycosis.